CTLA4 and neuroblastoma: Therefore, we show that even treatment over a relatively short time window (8 weeks) to accumulate enough immunogenic mutations in neuroblastoma tumors is sufficient to induce T cell infiltration into these poorly immunogenic tumors and sensitizes them to anti-CTLA4 treatment.